Dr. Damaj is the co-founder, CEO and CSO of Bio-Quant since its inception. Dr. Damaj brings to the company numerous years of biotechnology and pharmaceutical experience in drug discovery and development. Before joining the company, Dr. Damaj served as President & CEO of BioSignature Diagnostics, Inc. He also served as the Group Leader for the Office of New Target Intelligence and a Group Leader for immunological and inflammatory disease programs at Tanabe Research Laboratories, U.S.A., Inc. Previous appointments included Pharmacopeia Inc., a New-Jersey based company where Dr Damaj served as a senior scientist and a member of the senior staff board of the drug discovery department. He also was a visiting scientist at Genentech Inc., Pfizer Inc. and the NIH (NIAID). Dr. Damaj is the founder of Celltek Biotechnology, Mina Holdings, Biosignature Diagnostics and R&D Healthcare Inc. He holds numerous patents in this field and authored numerous peer reviewed scientific publications and is the author of the Immunological Reagents and Solutions reference book. Dr. Damaj served on several scientific advisory boards of biopharmaceuticals including Celltek, Virocell and Microislet, Inc. He is the holder of the US Congress Award for the development of the first Anthrax Diagnostic Blood Test for the United States in 2003. He also represented the State of California in the Congressional Scientific Liaison Committee in 2002. Dr. Damaj holds a Ph.D. in Immunology/Microbiology, a postdoctoral fellowship in molecular oncology and an MBA in healthcare. He was involved in over 7 drug candidates currently in clinical trials for a variety of diseases.